Rep. Kevin Hern Sells Off Shares of IQVIA Holdings Inc. (NYSE:IQV)

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of IQVIA Holdings Inc. (NYSE:IQV). In a filing disclosed on April 03rd, the Representative disclosed that they had sold between $50,001 and $100,000 in IQVIA stock on March 16th. The trade occurred in the Representative’s “HERN FAMILY REVOCABLE TRUST” account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Exact Sciences (NASDAQ:EXAS) on 3/24/2026.
• Sold $50,001 – $100,000 in shares of Prologis (NYSE:PLD) on 3/20/2026.
• Sold $15,001 – $50,000 in shares of T. Rowe Price Group (NASDAQ:TROW) on 3/20/2026.
• Sold $15,001 – $50,000 in shares of Medtronic (NYSE:MDT) on 3/20/2026.
• Sold $500,001 – $1,000,000 in shares of Texas Instruments (NASDAQ:TXN) on 3/18/2026.
• Sold $500,001 – $1,000,000 in shares of Smartstop Self Storage REIT (NYSE:SMA) on 3/18/2026.
• Sold $50,001 – $100,000 in shares of BlackRock MuniAssets Fund (NYSE:MUA) on 3/17/2026.
• Sold $15,001 – $50,000 in shares of Cognizant Technology Solutions (NASDAQ:CTSH) on 3/17/2026.
• Sold $15,001 – $50,000 in shares of Invesco (NYSE:IVZ) on 3/17/2026.
• Sold $15,001 – $50,000 in shares of Becton, Dickinson and Company (NYSE:BDX) on 3/17/2026.

IQVIA Stock Performance

Shares of IQVIA stock opened at $170.66 on Tuesday. The company has a market capitalization of $28.96 billion, a PE ratio of 21.71, a PEG ratio of 1.67 and a beta of 1.39. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $247.04. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.09. The stock’s fifty day simple moving average is $178.70 and its 200 day simple moving average is $204.76.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, topping the consensus estimate of $3.40 by $0.02. The business had revenue of $4.36 billion for the quarter, compared to the consensus estimate of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The firm’s revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the business posted $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Wall Street Zen raised IQVIA from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Weiss Ratings reiterated a “hold (c)” rating on shares of IQVIA in a report on Thursday, January 22nd. Royal Bank Of Canada initiated coverage on IQVIA in a report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 target price for the company. UBS Group lowered their target price on IQVIA from $280.00 to $240.00 and set a “buy” rating for the company in a report on Friday, February 6th. Finally, BMO Capital Markets set a $250.00 target price on IQVIA in a report on Friday, February 6th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, IQVIA currently has an average rating of “Buy” and an average target price of $229.13.

Hedge Funds Weigh In On IQVIA

Large investors have recently added to or reduced their stakes in the company. Ameliora Wealth Management Ltd. bought a new position in shares of IQVIA in the 4th quarter valued at about $25,000. Physician Wealth Advisors Inc. grew its holdings in shares of IQVIA by 1,340.0% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 134 shares in the last quarter. International Assets Investment Management LLC bought a new position in shares of IQVIA in the 4th quarter valued at about $27,000. Gilpin Wealth Management LLC bought a new position in shares of IQVIA in the 4th quarter valued at about $27,000. Finally, CrossGen Wealth LLC bought a new position in shares of IQVIA in the 4th quarter valued at about $28,000. Institutional investors own 89.62% of the company’s stock.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.